Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Allogeneic HCT Provides OS Benefit Independent of TP53 Allelic Status in MDS

November 18th 2023

Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status.

Increased Understanding of the Mechanisms of Myelofibrosis Helps Usher in New Treatments and Novel Agents

November 16th 2023

Gaby Hobbs, MD, discusses how research into the biology of myelofibrosis has propelled the development of novel therapies for this patient population and highlights the role that biomarkers play in the diagnosis, prognosis, and treatment response evaluation for these patients.

Momelotinib Approaches EU Approval for Myelofibrosis With Anemia

November 14th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion supporting the approval of momelotinib for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anemia with primary myelofibrosis, post–polycythemia vera myelofibrosis, or post–essential thrombocytopenia myelofibrosis who have not been exposed to a JAK inhibitor or who had received prior ruxolitinib.

Dr Tremblay on the Identification and Prevalence of MDS/MPN Overlap Syndromes

November 10th 2023

Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.

FDA Approval of Momelotinib May Establish New SOC for Myelofibrosis With Anemia

November 2nd 2023

Andrew T. Kuykendall, MD, discusses the importance of the approval of momelotinib in the treatment of patients with anemic symptomatic myelofibrosis, key efficacy and safety data from the MOMENTUM trial that supported the decision, and unanswered questions regarding the agent’s potential role in other subsets within this population.

Dr Hunter on the Ongoing Investigation into JAK Inhibitors in Myelofibrosis

October 26th 2023

Anthony M. Hunter, MD, discusses the evolution of JAK inhibitors in myelofibrosis, a topic that was highlighted in a presentation at the 2023 SOHO Annual Meeting.

Dr DiNardo on the FDA Approval of Ivosidenib in Relapsed/Refractory, IDH1+ MDS

October 24th 2023

Courtney D. DiNardo, MD, MSCE, discusses the significance of the FDA approval of ivosidenib in patients with relapsed/refractory, IDH1-mutated myelodysplastic syndromes.

FDA Approves Ivosidenib for Relapsed/Refractory IDH1-Mutant MDS

October 24th 2023

The FDA has approved ivosidenib (Tibsovo) for the treatment of adult patients with relapsed/refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.

Dr Kuykendall on Frontline Cytoreductive Therapies in Polycythemia Vera

October 21st 2023

Andrew Kuykendall, MD, discusses frontline cytoreductive treatment options for patients with polycythemia vera.

Dr Zhou on Ongoing Investigations into the Treatment of Patients With Myelofibrosis and Anemia

October 20th 2023

Amy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.

Newer-Generation JAK Inhibitors Expand Myelofibrosis Treatment Paradigm

October 19th 2023

Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.

Dr Zhou on the Use of Combination Therapies in Myelofibrosis

October 13th 2023

Amy W. Zhou, MD, discusses combination therapies with ruxolitinib that may contribute to the treatment paradigm for patients with myelofibrosis, highlighting the importance of continued research with phase 3 confirmatory trials for patients with this disease.

Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

October 11th 2023

The addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myeloid leukemia and those with myelodysplastic syndrome who were refractory to hypomethylating agents.

Dr Parrondo on the Clinical Benefit of Momelotinib on Anemia in Myelofibrosis

October 6th 2023

Ricardo D. Parrondo, MD, discusses the clinical benefit seen with momelotinib in anemic myelofibrosis, and where it fits into the current treatment paradigm in this disease landscape.

EMA Validates MAA for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS

October 3rd 2023

The European Medicines Agency has validated the marketing authorization application for the use of imetelstat in the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome.

Dr Zhou on the Evaluation of Combination Therapies With Ruxolitinib in Myelofibrosis

September 28th 2023

Amy W. Zhou, MD, discusses the investigation of ruxolitinib given in conjunction with novel or emerging agents such as pacritinib and momelotinib, highlighting these agents’ potential at contributing to the treatment paradigm in myelofibrosis.

State of the Science Summit - Hematology: Chaired by Ricardo D. Parrondo, MD

September 27th 2023

State of the Science Summit - Hematology: Chaired by Ricardo D. Parrondo, MD

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26th 2023

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Investigation of Novel Management Strategies Continues to Mitigate Disease-Related Toxicities Across Hematologic Malignancies

September 26th 2023

Amy W. Zhou, MD, highlights the unique mechanism of action of the JAK1/2 and ACVR1 inhibitor momelotinib and the importance of ongoing investigations of JAK inhibitor combination therapies in myelofibrosis.

Future Perspectives in the Treatment of Polycythemia Vera

September 22nd 2023

John Mascarenhas, MD, and Joe Scandura, MD, PhD, close their discussion by highlighting what to look forward to in the future of polycythemia vera treatment.